| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | ALKS Alkermes Plc. | Parisi Samuel Joseph62 | VP, Finance (interim Pao) | Sell | 1,938 | $34.00 | $65,892.00 | -20.1% | -11.9% | -12.3% | |
| Feb 25, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 225,000 | $903.07 | $203,190,794.31 | - | -19.6% | +14.1% | |
| Feb 25, 2025 | JNJ Johnson & Johnson | Decker Robert J56 | VP Corporate Controller | Sell | 6,999 | $165.88 | $1,160,994.12 | -25.0% | -7.7% | +47.6% | |
| Feb 25, 2025 | ALKS Alkermes Plc. | Parisi Samuel Joseph62 | VP, Finance (interim Pao) | Sell | 3,743 | $35.26 | $131,978.18 | -32.7% | -14.4% | -11.2% | |
| Feb 24, 2025 | PAHC Phibro Animal Health Corp | Corcoran E Thomas61 | Director | Buy | 5,000 | $22.10 | $110,500.00 | +20.0% | +10.6% | +132.5% | |
| Feb 24, 2025 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 17,303 | $48.14 | $832,966.42 | -8.2% | +4.0% | -69.9% | |
| Feb 24, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 60,432 | $857.54 | $51,823,021.51 | - | -17.7% | +18.2% | |
| Feb 24, 2025 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | CEO | Buy | 100,000 | $0.18 | $17,990.00 | - | - | - | |
| Feb 24, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina53 | Chief Legal Officer | Sell | 4,169 | $3.15 | $13,144.86 | -3.0% | +57.6% | +391.2% | |
| Feb 24, 2025 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 10,000 | $360.76 | $3,607,554.55 | -34.8% | -12.1% | +32.1% | |
| Feb 21, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Rubin Jonathan | SVP, Chief Medical Officer | Sell | 927 | $39.15 | $36,292.05 | -10.6% | -3.1% | +53.9% | |
| Feb 21, 2025 | DERM Journey Medical Corp | Benesch Joseph | CFO | Sell | 1,365 | $5.19 | $7,084.35 | -2.9% | +31.4% | +63.8% | |
| Feb 21, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 99,452 | $882.70 | $87,786,505.01 | - | -18.1% | +15.5% | |
| Feb 21, 2025 | ANIP Ani Pharmaceuticals Inc | Davis Krista45 | SVP, Chief Hr Officer | Sell | 1,000 | $60.20 | $60,200.00 | -1.4% | -1.2% | +34.2% | |
| Feb 20, 2025 | BMY Bristol Myers Squibb Co | Boerner Christopher S.60 | Chief Executive Officer | Buy | 2,000 | $55.05 | $110,096.00 | +1.9% | -15.8% | +8.7% | |
| Feb 20, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 14,685 | $877.99 | $12,893,352.83 | - | -17.0% | +15.6% | |
| Feb 20, 2025 | ALKS Alkermes Plc. | Parisi Samuel Joseph62 | VP, Finance (interim Pao) | Sell | 1,327 | $35.69 | $47,360.63 | -14.7% | -14.0% | -10.1% | |
| Feb 19, 2025 | MRK Merck & Co., Inc. | Oosthuizen Johannes Jacobus | President, U.s. Market | Sell | 8,500 | $84.09 | $714,744.60 | -21.7% | -8.9% | +42.4% | |
| Feb 19, 2025 | ZTS Zoetis Inc. | Peck Kristin C66 | Chief Executive Officer | Sell | 382 | $156.68 | $59,852.26 | -0.4% | +4.5% | -18.7% | |
| Feb 19, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 9,985 | $878.45 | $8,771,285.36 | - | -13.8% | +18.0% | |
| Feb 19, 2025 | ESPR Esperion Therapeutics, Inc. | Warren Eric60 | Chief Commercial Officer | Sell | 239 | $1.87 | $446.45 | -0.1% | -52.2% | +85.3% | |
| Feb 19, 2025 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 7,500 | $59.26 | $444,450.00 | -3.7% | -11.0% | -77.0% | |
| Feb 19, 2025 | ESPR Esperion Therapeutics, Inc. | Halladay Benjamin | Chief Financial Officer | Sell | 11 | $1.86 | $20.46 | - | -52.2% | +85.3% | |
| Feb 18, 2025 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 10,000 | $371.05 | $3,710,499.18 | -23.7% | -18.1% | +27.7% | |
| Feb 18, 2025 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 4,152 | $60.69 | $251,984.88 | -2.6% | +6.6% | -72.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.